Ascendis Pharma A/S $ 99.35 -0.73 (-0.73%)
Volume:
96,388
Avg Vol (1m):
214,224
Market Cap $:
4.70 Bil
Enterprise Value $:
3.96 Bil
P/E (TTM):
0.00
P/B:
6.13
Manual of Stocks™ Web
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 19.02 | ||
| Equity-to-Asset | 0.88 | ||
| Debt-to-Equity | 0.05 | ||
| Debt-to-EBITDA | -0.22 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 26.37 | ||
| Beneish M-Score | 17.86 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -954.07 | ||
| Net Margin % | -934.95 | ||
| ROE % | -38.56 | ||
| ROA % | -34.88 | ||
| ROC (Joel Greenblatt) % | -1109.16 | ||
| 3-Year Revenue Growth Rate | -7.6 | ||
| 3-Year EBITDA Growth Rate | -33.3 | ||
| 3-Year EPS without NRI Growth Rate | -33.5 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.13 | ||
| PS Ratio | 196.38 | ||
| EV-to-EBIT | -20.51 | ||
| EV-to-EBITDA | -20.87 | ||
| EV-to-Revenue | 182.15 | ||
| Current Ratio | 11.59 | ||
| Quick Ratio | 11.59 | ||
| Days Sales Outstanding | 0.08 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.14 | ||
| Price-to-Median-PS-Value | 1 | ||
| Earnings Yield (Greenblatt) % | -4.9 |